Abstract: Methods, apparatus and computer-readable media (transitory and non-transitory) are disclosed for analyzing a communication to or from a user to identify an event assumption and/or determine a likelihood that the communication is event-related. In various implementations, an accuracy of the event assumption, as well as an accuracy of the determined likelihood, may be assessed based on one or more scheduling signals, such as user-creation of a corresponding calendar entry. In various implementations, a machine learning classifier may be trained based at least in part on one or both accuracies.

Abstract: Disclosed are biomarkers, methods and assay kits for the identification of cancer patients who are predicted to benefit, or not to benefit, from the therapeutic administration of an epidermal growth factor receptor (EGFR) inhibitor. The biomarkers of the present invention include detection of EGFR and HER 2 gene amplification and polysomy, EGFR protein expression, EGFR mutations, phosphorylated Akt protein expression, and various combinations of such biomarkers, as well as the combination of these biomarkers with mutations in the tyrosine kinase domain of the EGFR gene. Increased EGFR gene copy number, increased HER2 gene copy number, increased EGFR protein expression, activated AKT protein expression (phosphorylated AKT) and EGFR mutations are all associated with better outcome for cancer patients treated with EGFR inhibitors.

Abstract: Disclosed are methods to obtain an expression score to evaluate gene expression in a tissue specimen obtained from a person having or suspected of having cancer.

Abstract: A computer device obtains a search query; obtains product search results based on the search query and a products search index that includes information regarding documents associated with products; determines a category associated with a set of result of the product search results; identifies candidate queries for the search query; determines whether the category matches one of the candidate queries; identifies that the search query is associated with a type of media identified by the category when the category matches one of the candidate queries; and provides, in response to identifying that the search query is associated with the type of media, a result document based on the type of media.

Abstract: A routing protocol is used to transmit messages from a sender to a receiver over a network of nodes, where adversaries can control links between the nodes and can also control the behavior of a large number of nodes. Various techniques can be used, along or in combination, to combat these effects. In one approach, certain trigger conditions are identified, the occurrence of which signals malicious behavior within the network. When signaled, the sender requests status reports from the intermediate nodes in an effort to determine which nodes are malicious. The information for the status reports is generated by nodes as packets are passed from one node to the next.

Abstract: A computer device obtains a search query; obtains product search results based on the search query and a products search index that includes information regarding documents associated with products; determines a category associated with a set of result of the product search results; identifies candidate queries for the search query; determines whether the category matches one of the candidate queries; identifies that the search query is associated with a type of media identified by the category when the category matches one of the candidate queries; and provides, in response to identifying that the search query is associated with the type of media, a result document based on the type of media.

Abstract: A ranked list of first search results based on a search query may be associated with a first search category, and each first search result may be associated with a first score. A ranked list of second search results based on the search query may be associated with a second, different search category, and a second search result may be associated with a second score. A final second score may be determined based on the second score and a function that maps scores associated with the second search category to scores associated with the first search category, information may be inserted relating to the ranked list of second search results at a position within the ranked list of first search results to form a set of search results, and the set of search results may be provided.

Abstract: Flurbiprofen analog compounds having an amino acid derivatized at the flurbiprofen alkanoic acid carboxyl group and terminating at an ester or amide group are effective in inhibiting cancer cells in vitro and inhibiting the growth of cancers in viva. The compounds and pharmaceutical compositions containing them are particularly useful for the treatment of lung, pancreatic and head and neck cancers.

Abstract: Disclosed are biomarkers, methods and assay kits for the identification of cancer patients who are predicted to benefit, or not to benefit, from the therapeutic administration of an epidermal growth factor receptor (EGFR) inhibitor. The biomarkers of the present invention include detection of EGFR and HER 2 gene amplification and polysomy, EGFR protein expression, EGFR mutations, phosphorylated Akt protein expression, and various combinations of such biomarkers, as well as the combination of these biomarkers with mutations in the tyrosine kinase domain of the EGFR gene. Increased EGFR gene copy number, increased HER2 gene copy number, increased EGFR protein expression, activated AKT protein expression (phosphorylated AKT) and EGFR mutations are all associated with better outcome for cancer patients treated with EGFR inhibitors.

Abstract: Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to EGFR inhibitors, and products and processes related thereto. In one embodiment, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.

Abstract: Disclosed is the use of a combination of histone deacetylase inhibitors and kinase inhibitors with anti-EGFR activity.

Abstract: Provided herein are methods for identifying a cancer patient responsive to treatment with an EGFR tyrosine kinase inhibitor. One method comprises obtaining a biopsy from the patient and measuring the number of copies of miR-128b in DNA extracted from the biopsy. A patient responsive to EGFR tyrosine kinase inhibitor treatment has a cancer with less than two copies of miR-128b DNA. Another method comprises measuring miR-128b or miR-128a level in a biopsy obtained from the patient and comparing that level to miR-128b or miR-128a level in a normal tissue sample. A patient responsive to treatment with an EGFR tyrosine kinase inhibitor has a cancer expressing a lower level of miR-128b or miR-128a relative to normal tissue. Further provided herein are methods for treating cancer in a patient in need thereof. One method comprises measuring the level of miR-128b or miR-128a in a biopsy obtained from the patient and administering to the patient an EGFR tyrosine kinase inhibitor.

Abstract: Flurbiprofen analog compounds having an amino acid derivatized at the flurbiprofen alkanoic acid carboxyl group and terminating at an ester or amide group are effective in inhibiting cancer cells in vitro and inhibiting the growth of cancers in viva. The compounds and pharmaceutical compositions containing them are particularly useful for the treatment of lung, pancreatic and head and neck cancers.

Abstract: Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to gefitinib and other EGFR inhibitors, and products and processes related thereto. Specifically, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for the detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.

Abstract: A routing protocol is used to transmit messages from a sender to a receiver over a network of nodes, where adversaries can control links between the nodes and can also control the behavior of a large number of nodes. Various techniques can be used, along or in combination, to combat these effects. In one approach, certain trigger conditions are identified, the occurrence of which signals malicious behavior within the network. When signaled, the sender requests status reports from the intermediate nodes in an effort to determine which nodes are malicious. The information for the status reports is generated by nodes as packets are passed from one node to the next.

Abstract: The invention provides bradykinin antagonists and pharmaceutically acceptable salts thereof having anti-cancer activity. These anti-cancer compounds are particularly useful for inhibiting the growth of lung and prostate cancers.

Abstract: Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to EGFR inhibitors, and products and processes related thereto. In one embodiment, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.

Abstract: The invention provides bradykinin antagonists and pharmaceutically acceptable salts thereof having anti-cancer activity. These anti-cancer compounds are particularly useful for inhibiting the growth of lung and prostate cancers.

Abstract: Disclosed is the use of a combination of histone deacetylase inhibitors and epidermal growth factor receptor (EGFR) inhibitors to treat cancer.

Abstract: The invention provides bradykinin antagonists and pharmaceutically acceptable salts thereof having anti-cancer activity. These anti-cancer compounds are particularly useful for inhibiting the growth of lung and prostate cancers.